|Articles|August 29, 2012

Even With the New Deadline, 'Time is Running Out' on ICD-10

CD-10

Now that the Department of Health and Human Services has decided on the new I deadline, one reality not to be overlooked is that October 1, 2014 is a mere two years away.

That doesn't leave a lot of time for healthcare organizations to meet the mandate, particularly those who have not yet even started the conversion. Deb Grider, senior manager of Blue & Co. consultancy, talks about how she sees the new deadline being perceived in healthcare, discusses the reality of some health entities still being in denial that ICD-10 will happen and suggests how those already into the transition can adjust their plans to make use of the extra year.

Read the full story: http://tinyurl.com/9g7zu9w

Source: Healthcare Payer News

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

On-Demand Webinar

Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies

1.0 Credit / Psychiatry

Even With the New Deadline, 'Time is Running Out' on ICD-10

Newsletter

Related Content

Measles Outbreaks Cause Financial, Public Health Burden in US

Walking Carefully With Masks, Avoiding Projectiles Are Key in Protecting Eyes on Halloween: Douglas Lazzaro, MD

Innovative Payment Models, Holistic Medicaid Approaches Could Improve GLP-1 Access, Outcomes

Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC

Combination and Monotherapy Data Highlight Rocatinlimab’s Real-World Potential in AD: A Q&A With Emma Guttman-Yassky, MD, PhD

Latest CME

Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies

Closing Gaps in CLL Care: Managed Care Insights and Strategies

Revolutionizing Acute Pain Relief: Emerging Non-Opioid Therapies and the Essential Role of Pharmacists

Overview and Burden of Migraine

The Role of the Pharmacist Migraine Management

The Evolving Treatment Landscape of Migraine

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

New and Approved: FDA’s 2024 Drug Lineup

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed Care

Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer

Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

Managed Care Approaches and Models for Equitable Access to Innovations in Major Depressive Disorder Treatment

Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage

Leveraging Biologics and Immunotherapies in the Management of Food Allergies

Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)

Leveraging Novel Therapies to Transform Demodex Blepharitis Care

The Changing Paradigm in Pain Management and Supporting Access to Novel Therapies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Opioids, Pain Management, and Substance Use Disorder: A Practical Overview

Trending on AJMC

Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration

Boosting RSV Vaccination in Older Adults Could Save Thousands

FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development

Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain

Biktarvy Improves ART Persistence for People With HIV and Mental Health Disorders